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AbsTrACT
Aims The advent of immune checkpoint inhibitor 
therapy has proven beneficial in a subset of high- grade 
urothelial carcinomas (HGUC) of the bladder. Although 
treatment selection is currently largely determined by 
programmed death- ligand 1 (PD- L1) status, multiple 
factors in the immune system may modulate the host 
immune response to HGUC and immunotherapy. In this 
pilot study, we used a transcriptomic approach to identify 
the immune milieu associated with PD- L1 expression 
to enhance our understanding of the HGUC immune 
evasion network.
Methods The immune transcriptome of 40 HGUC 
cystectomy cases was profiled using the NanoString 
nCounter Human V.1.1 PanCancer Panel. All cases were 
assessed for associated PD- L1 status (SP263) using 
whole tissue sections. PD- L1 status was determined 
as high or low using 25% tumour and/or immune cell 
staining.
results The most significantly differentially expressed 
gene was PD- L1 messenger RNA (CD274), which 
strongly correlated with protein expression (r=0.720, 
p<0.001). The sensitivity, specificity, positive and 
negative predictive values of CD274 for PD- L1 expression 
were 85%, 96%, 92% and 93%, respectively. The PD- L1 
associated gene signature also included complement 
components C1QA and CD46 and NOD2 (innate immune 
system), proinflammatory cytokines CXCL14, CXCL16, 
CCL3, CCL3L1 and OSM along with the immune 
response mediator SMAD3, among others. Pathway 
analysis determined enrichment of these genes in 
interleukin-10 production, lymphocyte chemotaxis and 
aberrant IFNγ, NF-κB and ERK signalling networks.
Conclusions We report key genes and pathways in the 
immune transcriptome and their association with PD- L1 
status, which may be involved in immune evasion of 
HGUC and warrants further investigation.
InTrOduCTIOn
Patients diagnosed with high- grade muscle invasive 
urothelial carcinoma of the bladder (HGUC) have 
high rates of disease recurrence, progression and 
mortality despite optimal treatment with surgery 
(European Association of Urology and American 
Urology Association guidelines) and/or neoadjuvant 
and adjuvant therapy.1–5 Thus, novel therapeutic 
strategies for HGUC patients are being actively 
explored.
Recent advancements in immunology have led to 
immunotherapy taking centre stage in the treatment 
of urothelial carcinoma (UC). In particular, immune 
checkpoint inhibitors (ICIs), such as programmed 
cell death protein (PD-1) and programmed death- 
ligand 1 (PD- L1) inhibitors, have emerged as ther-
apeutic approaches for advanced and metastatic 
UC.6–10 However, only a subset of patients benefit 
from these inhibitors.11 Assessment of tumour and/
or immune- cell PD- L1 expression by immunohis-
tochemistry (IHC) is typically used as a comple-
mentary diagnostic to identify patients most likely 
to benefit from anti- PD-1/PD- L1 inhibitors, with 
better overall response rates noted in PD- L1- 
positive/high disease.12 Yet, the positive and nega-
tive predictive values of PD- L1 IHC as a biomarker 
for anti- PD-1/PD- L1 inhibitors are suboptimal. 
Additionally, conflicting results have been reported 
regarding the correlation between PD- L1 expres-
sion and patient survival.7 9 13–15
We now know that the response to anti- PD1/
PD- L1 therapy cannot be solely predicted by PD- L1 
IHC status. PD- L1 expression can be transient and 
heterogeneous12 and is modulated by numerous 
molecular mechanisms within the tumour and 
its microenvironment.16 17 PD- L1 IHC does not 
take into account the state of active immune cell 
engagement of the PD-1/PD- L1 axis and its interac-
tion with tumour microenvironment, nor whether 
other concurrent suppressive immune pathways 
are activated. In this regard, targeted gene expres-
sion panels have the ability to assess the tumour 
microenvironment and immune milieu of UCs 
more comprehensively.12 A wide range of cytokines 
in the tumour microenvironment can promote 
tumour immune escape and induce the expression 
of PD- L1.18 Therefore, immune gene expression 
profiling has the potential to ascertain the inflam-
matory status of a tumour by quantifying chemok-
ines, cytokines and cell surface proteins along with 
CD274 levels.
As a first step to understanding discrepancies in 
therapeutic response to ICI, we sought to evaluate 
the transcriptome of PD- L1 IHC high and PD- L1 
IHC low HGUC. In this pilot study, our aims 
were (1) to determine the degree of concordance 
between PD- L1 IHC and messenger RNA (mRNA) 
levels of CD274 and (2) identify whether there 
was a specific immune gene expression signature 
(eg, chemotaxis, leucocyte activation, suppression 
of T cell activation suppression and regulation of 
ERK1/ERK2 cascade) associated with PD- L1 status 
in HGUC.
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Table 1 Clinicopathological characteristics of the cohort (n=40)
Characteristic n (%)
Age (years)
  Mean 69.8
33 to 88  Range
Sex
  Male 28 (70.0)
  Female 12 (30.0)
CIS
  Present 18 (45.0)
  Absent 22 (55.0)
pT stage
  pT1 1 (2.5)
  pT2 0 (0.0)
  pT3 29 (72.5)
  pT4 10 (25.0)
AJCC stage
  I 1 (2.5)
  II 0 (0.0)
  III 27 (67.5)
  IV 12 (30.0)
Surgical margins
  Positive 13 (32.5)
  Negative 27 (67.5)
Lymphovascular invasion
  Present 29 (72.5)
  Absent 11 (27.5)
Lymph node metastases
  Present 12 (30.0)
  Absent 25 (62.5)
  N/A 3 (7.5)
AJCC, American Joint Committee on Cancer; CIS, Carcinoma In Situ; pT, Pathologic T category.
MATerIAls And MeThOds
Case selection and review
This study was approved by the Research Ethics Board at Sunny-
brook Health Sciences Centre (REB 187–2016). A subset of 40 
HGUC (≥pT2) bladder cystectomy cases (1999 to 2015) was 
identified from a larger cohort19 of 235 cases through a retro-
spective search of the laboratory information system, Sunquest 
CoPath. Six patients were BCG treated, all others were treat-
ment naïve. Exclusion criteria were non- urothelial histology, 
presence of any neuroendocrine carcinoma component and 
divergent differentiation encompassing >50% of the tumour. 
Only tumours with clinical follow- up and sufficient tumour 
blocks were selected for the NanoString work. The complete 
set of H&E- stained slides from each cystectomy was collected 
and reviewed by a urological pathologist (MRD), to confirm 
tumour histology, grade (according to the 2016 WHO/Interna-
tional Society of Urological Pathology guidelines), pathological 
stage (American Joint Committee on Cancer immunohistochem-
istry (AJCC)/tumour, node, metastases (TNM) eighth edition), 
presence of carcinoma in situ, lymphovascular invasion, nodal 
metastases and margin status.
Immunohistochemistry
Whole tissue section PD- L1 expression was determined with 
the Ventana SP263 (Ventana Medical Systems, Tucson, Arizona, 
USA) antibody according to manufacturer's protocol. PD- L1 
staining was scored as high when >25% tumour cells (TC) or 
immune cells (IC) staining was seen, according to manufactur-
er's recommendations. TC staining was defined as either partial 
or complete membranous staining of any intensity. IC staining 
was defined as either cytoplasmic or membranous staining of 
any intensity. The identification of TCs and ICs was based on 
morphological features on H&E- stained slides. Both TC and 
IC staining were assessed as either present or absent. Interpre-
tation of immunohistochemically stained slides were conducted 
by one genitourinary pathologist (MRD) blinded to all case 
characteristics.
rnA isolation and gene expression profiling
A single representative formalin- fixed, paraffin- embedded 
(FFPE) tissue block stored at room temperature was selected 
from each case for RNA extraction and sectioned at a thickness 
of 5 µm (4 to 10 sections per case). Representative tumour areas 
were outlined on the unstained slides and macrodissected within 
7 days. Total RNA was extracted from the macrodissected tissue 
using high- pure FFPET RNA Isolation Kit (Roche Diagnostics, 
Indianapolis, Indiana, USA), per manufacturer's instructions. 
RNA profiling was performed with 250 ng (quantified using 
NanoDrop-1000, Thermo Fisher Scientific, Waltham, Massa-
chusetts, USA) of RNA using the NanoString nCounter Human 
V.1.1 PanCancer Immune Profiling Panel (NanoString Technol-
ogies Inc, Seattle, Washington, USA), according to the manufac-
turer’s instructions.
Raw gene expression data was analysed using NanoString's 
software nSolver V.4.0 with the Advanced Analysis 2.0 plugin. 
Data normalisation was performed using internal negative control 
probes, synthetic positive controls and 36 selected housekeeping 
genes that were identified using the nSolver normalisation module, 
which uses the geNorm algorithm (https:// genorm. cmgg. be/). Data 
was normalised using geometric mean, log2- transformed and then 
used as input for further analysis. P values were adjusted using the 
Benjamini- Hochberg (BH) method to control the false discovery 
rate (FDR). Statistically significant, differentially expressed genes 
(DEGs) were defined as those with expression levels corre-
sponding to a log2 ratio >1 or <−1 and BH q<0.05. Functional 
and pathway enrichment analysis was performed using g:Profiler 
(V.e94_eg41_p11_9f195a1) with a BH- FDR multiple testing 
correction method applying significance threshold of 0.05.
statistical analysis
All statistical analyses were performed with SPSS 24.0 (IBM 
Corporation, Armonk, New York, USA). Comparisons between 
PD- L1 expression (high, low) and continuous data were performed 
using the Mann- Whitney U test while comparisons between binary 
PD- L1 expression and categorical variables were performed using 
the Fisher's exact test. For all described methods, two- sided P 
values less than 0.05 were considered statistically significant. 
Correlation between PD- L1 and CD274 expression was assessed 
using Pearson correlation. The continuous CD274 expression 
variable was dichotomised using receiver operating characteristic 
(ROC) analysis. Briefly, ROC analysis was performed to deter-
mine the threshold value that allowed optimal separation between 
PD- L1 IHC high versus low cases with maximum combined sensi-
tivity and specificity. The NanoString CD274 mRNA expression 
threshold value used was 3.7, assigning cases into positive (RNA 
abundance >3.7) and negative (RNA abundance <3.7) groups. 
Sensitivity, specificity, positive and negative predictive values were 
calculated using this cut- off with true positive defined as PD- L1 
IHC high, true negative defined as PD- L1 IHC low, false positive 
defined as CD274 mRNA expression positive but PD- L1 IHC low 
and false negative defined as CD274 mRNA expression negative 
but PD- L1 IHC high.
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Figure 1 (A) High and (B) low PD- L1 immunoexpression (Ventana 
SP263 IHC assay), compared with (C) mRNA expression of CD274 in 
PD- L1 high versus PD- L1 low high- grade urothelial carcinomas of the 
bladder, box and whisker plot. (D) Receiver operating characteristic 
(ROC) curve illustrating the performance of CD274 mRNA expression 
in predicting PD- L1 protein detection by IHC. The sensitivity, specificity, 
positive and negative predictive values of PD- L1 mRNA expression 
for protein detection by IHC, using the optimal cut- off 3.7 (maximum 
combined sensitivity and specificity), were 85%, 96%, 92% and 93%, 
respectively. AUC, area under the curve; IHC,immunohistochemistry; 
mRNA, messenger RNA; PD- L1, programmed death- ligand 1.
Table 2 Differentially expressed genes between PD- L1 (SP263) high 
versus PD- L1 (SP263) low high- grade urothelial bladder carcinoma 
cases
mrnA linear fold change Fdr (bh) P- Value
CD274 5.6 <0.001
C1QA 3.7 0.044
PDCD1LG2 3.0 0.001
CTSH 3.0 0.047
SIGLEC1 3.0 0.007
CD46 2.9 0.002
CXCL14 2.7 0.030
CCL3 2.7 0.015
CXCL16 2.6 0.044
NOD2 2.6 0.044
OSM 2.6 0.037
LILRB1 2.5 0.044
CCL3L1 2.0 0.044
FCER1G −2.4 0.001
C1QB −3.3 0.009
SMAD3 −4.4 0.028
BH, Benjamini- Hochberg method; FDR, false discovery rate; mRNA, messenger RNA; PD- L1, 
programmed death- ligand 1.
resulTs
The study population was composed of 40 patients with HGUC 
of bladder (≥pT2) treated by cystectomy (1999 to 2015). Clin-
icopathological parameters of the cohort are summarised in 
table 1. No patients received neither neoadjuvant nor adjuvant 
immunotherapy.
Correlation of CD274 mrnA and Pd-l1 protein expression
We examined the relationship between PD- L1 protein expression 
detected by IHC and CD274 mRNA (which encodes the PD- L1 
protein) expression levels (figure 1C). We found CD274 mRNA 
strongly correlated with PD- L1 protein expression (Pearson's 
correlation coefficient r=0.720, p<0.001). ROC analysis was 
then performed to determine the optimal threshold of CD274 
mRNA expression level to predict the PD- L1 IHC results (high 
vs low) with maximum combined sensitivity and specificity. The 
NanoString CD274 RNA abundance level threshold value was 
determined to be 3.7. Sensitivity, specificity, positive and negative 
predictive values of CD274 expression for PD- L1 protein detection 
by IHC at this cut- off were 85%, 96%, 92% and 93%, respectively 
(figure 1D). IHC and RNA profiling were discordant in three (8%) 
HGUC cases. Of these, two were PD- L1 IHC high based solely on 
IC staining while the CD274 mRNA expression in these cases was 
below the RNA expression cut- off value determined by ROC.
Identification of an immune gene expression signature 
associated with Pd-l1 expression
To characterise the immune milieu associated with PD- L1 IHC 
in our cohort, gene expression profiles were analysed using an 
immune cancer gene panel of 770 genes (NanoString Technolo-
gies). More concretely, we sought to identify genes with differen-
tial expression values between PD- L1 IHC high and PD- L1 IHC 
low samples which would allow us to delineate which genes in 
the immune transcriptome are informative of PD- L1 mediated 
immune evasion. We found that PD- L1 protein expression is 
associated with a gene signature containing 16 significantly DEGs 
(table 2, figure 2A). As expected, the most significantly differen-
tially expressed gene was CD274 (encodes PD- L1).
Pathway analysis (figure 2B) determined enrichment of these 
16 DEGs in production of interleukin-10 (eg, CD46, NOD2) 
previously shown to induce PD- L1 expression, lymphocyte 
chemotaxis (eg, CXCL14, CXCL16), leucocyte activation (eg, 
CD46, NOD2), suppression of T cell activation (eg, FCER1G, 
PDCD1LG2) and regulation of ERK1/ERK2 cascade (eg, 
CXCL16, CCL3) known to be involved in PD- L1 upregulation. 
Notably, NOD2 and FCER1G are also involved in activation of 
NF-κB, a transcription factor involved in activation of PD- L1 
transcription.
dIsCussIOn
In this pilot study, we have shown that detection of PD- L1 
RNA in FFPE clinical samples using NanoString- based profiling 
demonstrates high sensitivity and specificity with protein detec-
tion using a commercially available PD- L1 IHC assay (Ventana 
SP263). Evaluation of the immune milieu of these tumours by 
NanoString suggests that the key genes in the immune transcrip-
tome that are associated with PD- L1 mediated immune evasion 
are complement components C1QA and CD46 as well as NOD2 
signalling (innate immune system), proinflammatory cytokines 
CXCL14, CXCL16, CCL3, CCL3L1 and OSM along with the 
immune response mediator SMAD3 (transforming growth factor 
beta (TGFβ) signalling).
Our findings are in line with several other studies reporting 
strong correlation between PD- L1 protein IHC and mRNA 
measured by NanoString, RNA- seq and reverse transcription 
(RT)- quantitative PCR technologies.20–23 However, others 
have found weak or no correlation between PD- L1 mRNA and 
IHC.24 25 This is likely related to different mRNA quantifica-
tion methods and IHC protocols (RNA in situ hybridisation, 
RT- PCR, different IHC protocols, antibody clones and quan-
tification). In this regard, important advantages of the NanoS-
tring technology are its applicability to FFPE samples and digital 
counting proving a direct measurement of mRNA levels without 
amplification bias. Our NanoString immune transcriptome 
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Figure 2 (A) Volcano plot of differentially expressed genes between PD- L1 (SP263) high versus low high- grade urothelial bladder carcinoma 
(HGUC) cases. Three genes were significantly (log2 ratio >1 and BH q value<0.05) more abundant in PD- L1 low HGUC (red data points), and 13 genes 
were significantly more abundant in PD- L1 high HGUC (green data points). (B) Bar graph depicting enriched GO terms by g:Profiler analysis of the 
16 significantly differentially expressed genes between PD- L1 (SP263) high versus low cases. BH,Benjamini- Hochberg method; PD- L1, programmed 
death- ligand 1.
analysis of HGUC identified a 16 immune gene expression 
signature associated with PD- L1 expression. The findings indi-
cate a cross- talk between PD- L1 in the adaptive immunosup-
pressive pathway and the innate immune response genes C1QA, 
CD46 (complement system) and NOD2 (NOD2 signalling). 
C1QA encodes for subunit A of the complement C1q protein, 
which has been shown to act as a tumour- promoting factor by 
promoting tumour proliferation, adhesion, migration, angiogen-
esis and metastasis.26 Although the mechanism that links PD- L1 
and C1QA gene expression has not been yet examined, it has 
been shown that other complement components (C3a and C5a) 
can induce PD- L1 expression through the activation of ERK1/
ERK2 and JNK signalling pathways.27 CD46 is a complement 
regulatory protein that regulates various T- cell subsets during 
an active immune response.28 Specifically, the binding of CD46 
on CD4 + T cells has been found to promote T- helper type 
1 cell proliferation and activation along with upregulation of 
interleukin-10 (IL-10) and IFNγ, a cytokine that regulates the 
expression of PD- L1.28 Another member of the innate inflamma-
tory system, NOD2, is primarily involved in immune response 
to bacteria and viruses through the activation of IL-10, NF-κB, 
MAPkinase (MAPK) and caspase-1 pathways, which leads to 
increased expression of proinflammatory factors and PD- L1.29 30 
Notably, both CD46 and NOD2 have been shown to modulate 
expression of the cytokine IL-10. Although IL-10 itself has not 
been shown to directly induce the expression of PD- L1, inhibi-
tion of IL-10 in the tumour microenvironment has been linked 
to decreased expression of PD- L1.18
Studies have shown that a myriad of cytokines in the tumour 
microenvironment can induce the expression of PD- L1 and 
promote tumour immune escape.18 In our HGUC cohort, the 
proinflammatory chemokines CXCL14, CXCL16, CCL3 and 
CCL3L1 as well as the OSM cytokine were all upregulated in 
association with PD- L1 expression, indicating a potential cross- 
talk between these genes in tumour immune tolerance and 
progression of HGUC.
The proinflammatory chemokine CXCL14 is mainly involved 
in stimulating chemotaxis of various immune cells including 
NK cells, B cells and macrophages.31 However, the exact 
molecular mechanisms by which CXCL14 mediates immune 
response are unknown. To date, CXCL14 expression has been 
linked to calcium influx, NF-κB activity, activation of AP-1, 
NOS1 and MEK- ERK. Of note, NF-κB and ERK activity has 
also been linked to PD- L1 expression. The chemokine CXCL16 
also induces chemotaxis and its expression has been shown to 
be induced by IFNγ, leading to activation of the ERK1/ERK2 
signalling pathway and promotion of tumour proliferation.32 
The chemotactic proinflammatory chemokine, CCL3, is known 
to enhance leucocyte infiltration to sites of acute inflammation, 
as seen in cancer.33 This is consistent with our results indicating 
positive correlation between CCL3 and PD- L1 expression as 
tumor infiltrating lymphocytes have been shown to overexpress 
PD- L1 to inhibit antitumour immune response.33 Further, we 
report a positive correlation between the expression of PD- L1 
and the chemotactic, proinflammatory chemokine, CCL3L1. 
This chemokine has been shown to be functionally involved 
in proliferation of leukocytes, lymphocytes and macrophages 
as well as tumourigenesis of glioblastoma.34 Lastly, we found 
association between expression of PD- L1 and the proinflamma-
tory cytokine OSM which has been shown to stimulate several 
signalling pathways (Janus kinases/signal transducer and acti-
vator of transcription proteins, MAPK and PI3 kinase), some of 
which are involved in the upregulation of PD- L1 expression.35 
Our findings imply cross- talk between PD- L1 expression and 
downregulation of SMAD3 (key component of TGFβ signalling) 
in inhibition of antitumour immunity. This is consistent with 
previous reports that SMAD3- deficient mice have increase in 
constitutively activated T cells and expression of cytokines such 
as IL-2, IL-13, IL-15 and IFNγ.36
In conclusion, we identified significant correlation between 
PD- L1 IHC and CD274 mRNA levels. We further identified 
different gene expression profiles in PD- L1 high versus PD- L1 
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low HGUC. These initial findings are encouraging and warrant 
further exploration in ICI treated cohorts to assess how these 
gene expression profiles correlate with therapeutic outcome.
Take home messages
 ► There is a significant correlation between programmed death- 
ligand 1 (PD- L1) immunohistochemistry (Ventana SP263) and 
CD274 messenger RNA levels (NanoString profiling) in high- 
grade urothelial carcinoma (HGUC) of the bladder.
 ► NanoString immune profiling of HGUC identified a 16 gene 
signature associated with PD- L1 expression including C1QA, 
CD46, NOD2 (innate immune system), proinflammatory 
cytokines CXCL14, CXCL16, CCL3, CCL3L1 and OSM 
along with the immune response mediator SMAD3 (TGFβ 
signalling)
 ► Key pathways in the immune transcriptome associated with 
PD- L1 status are interleukin-10 production, lymphocyte 
chemotaxis and aberrant IFNγ, NF-κB and ERK signalling 
networks.
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